Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,802.00
Bid: 1,808.00
Ask: 1,814.00
Change: 48.00 (2.74%)
Spread: 6.00 (0.332%)
Open: 1,740.00
High: 1,830.00
Low: 1,740.00
Prev. Close: 1,754.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CORRECTION: Outcome of IntelliGen Litigation

11 Sep 2019 08:02

RNS Number : 9483L
Genus PLC
11 September 2019
 

This announcement replaces RNS number 9356L issued this morning, removing the word "million" from the number of straws sold by ABS up to 30 June 2019. All other information in the announcement remains unchanged.

 

 

For Immediate Release 11 September 2019

Genus plc

('Genus')

Outcome of latest IntelliGen Litigation

Genus plc (LSE: GNS), a global pioneer in animal genetics, announces that on 10 September 2019 the jury in the US District Court for the Western District of Wisconsin considered damages in the IntelliGen litigation. On 9 September 2019, as previously announced, the jury held that Genus' sexed semen technology, sold by ABS Global, Inc., under the IntelliGen brand, infringed three patents asserted by Inguran, LLC and Cytonome/ST, LLC (collectively "ST").

The jury held that ABS should pay a royalty of $2.60 per straw sold for the infringement of US patents 7,311,476 ("'476") and 7,611,309 ("'309") for 3,295,355 straws sold by ABS up to 30 June 2019. This royalty will be retrospective only, as ABS has already reengineered the IntelliGen technology by incorporating its non-infringing microfluidic chip known as "SSC(B)". ST confirmed in Court that the SSC(B) does not infringe the '476 or '309 patents. The infringement of the US Patent No. 8,206,987 confirms ABS' existing obligation to pay a royalty of $1.25 for each straw of sexed semen produced in the US. 

ABS is considering its options for appeal. 

 

For further information, please contact:

Genus Tel: +44 (0)1256 345970

Stephen Wilson, Group Finance Director

Dan Hartley, Group General Counsel and Company Secretary

Buchanan Tel: +44 (0)207 466 5000

Charles Ryland / Chris lane / Vicky Hayns

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAKNFFSNNEEF
Date   Source Headline
12th Oct 20184:37 pmRNSDirector/PDMR Shareholding
1st Oct 20182:00 pmRNSTotal Voting Rights
24th Sep 20186:01 pmRNSAdditional Listing
24th Sep 20181:52 pmRNSNon-Executive Director Retirement
19th Sep 20183:36 pmRNSDirector/PDMR Shareholding
18th Sep 20185:21 pmRNSDirector/PDMR Shareholding
17th Sep 20185:27 pmRNSDirector/PDMR Shareholding
6th Sep 20187:00 amRNSPreliminary Results
1st Aug 20182:00 pmRNSBlock listing Interim Review
20th Jul 201811:56 amRNSHolding(s) in Company
11th Jul 20181:44 pmRNSHolding(s) in Company
9th Jul 20187:00 amRNSHolding(s) in Company
20th Jun 20187:00 amRNSCapital Markets Event
12th Jun 20182:42 pmRNSDirector/PDMR Shareholding
24th May 20187:00 amRNSBoard Appointment
18th May 20185:22 pmRNSDirector/PDMR Shareholding
1st May 20184:39 pmRNSTotal Voting Rights
12th Apr 20186:18 pmRNSDirector/PDMR Shareholding
16th Mar 20182:34 pmRNSDirector/PDMR Shareholding
5th Mar 20186:38 pmRNSDirector/PDMR Shareholding
1st Mar 201810:48 amRNSHolding(s) in Company
28th Feb 20187:00 amRNSInterim Results
1st Feb 20182:00 pmRNSBlock listing Interim Review
29th Dec 201711:51 amRNSDirector/PDMR Shareholding
22nd Dec 201711:27 amRNSDirector/PDMR Shareholding
13th Dec 20175:48 pmRNSDirector/PDMR Shareholding
8th Dec 20174:41 pmRNSDirector/PDMR Shareholding
1st Dec 20172:00 pmRNSTotal Voting Rights
23rd Nov 201710:57 amRNSDirector/PDMR Shareholding
17th Nov 20172:15 pmRNSAdditional Listing to Correct Discrepancy
16th Nov 20172:49 pmRNSResult of AGM
16th Nov 20177:00 amRNSAGM Trading Update
6th Nov 201712:48 pmRNSDirector/PDMR Shareholding
2nd Nov 20172:01 pmRNSNon-Executive Director Retirement
1st Nov 20172:00 pmRNSTotal Voting Rights
31st Oct 20177:00 amRNSAdditional Listing
12th Oct 201710:39 amRNSNotice of AGM
2nd Oct 20172:00 pmRNSTotal Voting Rights
29th Sep 20177:08 amRNSDirector Declaration
21st Sep 20175:29 pmRNSDirector/PDMR Shareholding - Replacement
14th Sep 20175:30 pmRNSDirector/PDMR Shareholding
7th Sep 20177:00 amRNSPreliminary Results
1st Sep 20173:12 pmRNSTotal Voting Rights
17th Aug 20172:51 pmRNSHolding(s) in Company
1st Aug 20172:00 pmRNSBlock listing Interim Review
1st Aug 20172:00 pmRNSTotal Voting Rights
3rd Jul 20172:59 pmRNSTotal Voting Rights
29th Jun 20175:23 pmRNSAdditional Listing
12th Jun 20173:23 pmRNSHolding(s) in Company
9th Jun 20177:00 amRNSUS LITIGATION UPDATE

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.